Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: Involvement of enzyme inactivation

Drug Metabolism and Disposition

Volumn 28, Issue 4, 2000, Pages 460-466

  Lin, Jiunn H ^a   Chen, I Wu ^a   Chiba, Masato ^a   Nishime, Joy A ^a   Deluna, Florencia A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L 741051; L 754394; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BLOCKING; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; INDANS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MICROSOMES, LIVER; NONLINEAR DYNAMICS; PERFUSION; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; STEROID HYDROXYLASES; TESTOSTERONE;

ANIMALIA; CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034031395     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Buxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165-176.
2. Chiba M, Nishime JA and Lin JH (1995) Potent and selective inactivation of human liver microsomal cytochrome P450 isoforms hy L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527-1534.
3. Fujita S, Chiba M, Ohta M, Kitani K and Suzuki T (1940) Alteration of plasma sex hormone levels associated with old age and its effect on hepatic drug metabolism in rats. J Pharmacoi Exp Ther 253:369-374.
4. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev 50:387-411.
5. Lin JH (1994) Dose-dependent pharmacokineties: Experimental observations and theoretical considerations. Biopharm Drug Dispos 15:1-31.
6. Lin JH, Chiba M, Chen IW, Vastag KJ, Nishime JA, Dorsey BD, Michelson SR and McDaniel SL (1995) Time and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther 274:264-269.
7. Lin JH and Lu AYH (1997) Role of pharmacokinetics and drug metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
8. Lin JH and Lu AYH (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
9. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
10. Morris ME, Yuen V, Tang BK and Pang KS (1988) Competing pathways in drug metabolism 1: Effect of varying input concentrations on gentisamide conjugation in the once-through in situ perfused rat liver. J Pharmacol Exp Ther 245:614-624.
11. Sahali-Sahly Y, Balani SK, Lin JH and Baillie TA (1996) In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome 3A4. Chem Res Toxicol 9:1007-1012.
12. Silverman RB (1988) Criteria for mechanism-based enzyme inactivation, in Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology Chapter 1. pp 3-27, CRC Press, Boca Raton.
13. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.